Volume 8, Issue 3; January – March 2018

1. Design of Nanostructured Lipid Carriers Ubiquinone-10 for Transdermal Treatment
   M Farhan Rehman, Ionpens, Easi Hendra
   Abstract

   Sonbrin Karanja, Sunayana Mall, Ramaling Koti
   Abstract

3. Formulation and Evaluation of Tramadol Hydrochloride Sustained Release Matrix Tablets
   B Sai Adithya, Gulshan Mohammad, Rama Ran Adamu
   Abstract

4. Development and In Vitro Characterization of Solid Lipid Nanoparticles (SLN) Containing Methotrexate And Doxycycline
   Vigna R, Ram Kohan K R
   Abstract

5. Effect of Lipid Composition on Nanostructured Lipid Carrier (NLC) on ubiquinone Effectiveness as an Anti-aging Cosmetics
   Tomura Gskh Eliavarany, Vidi Smitri, Neema Rasha
   Abstract

Impact Factor: 1.529
This journal is present in UGC approved List of Journals for the purpose of Career Advancement Scheme (CAS) and Direct Recruitment of Teachers and other academic staff as required under the UGC (Minimum Qualifications for Appointment of Teachers and other Academic Staff in Universities and Colleges).

Other Journals published by International Society for Science and Nature

- WWW.UPQA.COM
  Internation Journal of Pharmaceutical Quality Assurance

- WWW.UPCR.COM
  International Journal of Pharmaceutical and Clinical Research

- WWW.UPPR.COM
  International Journal of Pharmacognosy and Phytochemical Research

- WWW.UICPR.COM
  International Journal of Current Pharmaceutical Review and Research

- WWW.UITPR.COM
  International Journal of Toxicological and Pharmacological Research
International Journal of
Drug Delivery Technology

ISSN: 0975 4415
Peer Review Journal

EDITOR IN CHIEF

Prof. Dina Nach Mishra
Professor and Head of Pharmacognosy, Department of Pharmaceutical Sciences,
Guru Jambheshwar University of Science and Technology, INDIA

Board Members

Dr. Shilpender K. Singh
Guru Jambheshwar University of Science and Technology, INDIA

Dr. Somnath Singh
Creighton University, Omaha, USA

Dr. Parshuram Roy
Himachal Institute of Pharmaceutical & Research, HP, INDIA

Dr. Tathagata Dutta
University of Queensland, Brisbane, AUSTRALIA

Dr. Ashish Suttee
Lovely Professional University, Phagwara, INDIA

Dr. Kelpanish Gaur
Gentsrail College of Pharmaceutical Studies, Udaipur, INDIA

Dr. Vishal Gupta
Director, Research & Development Covifien, USA

Dr. Chandan M. Thomas
Department of Pharmaceutical Sciences, Lake Erie College of Osteopathic Medicine and School of Pharmacy 5600 Lakeshore Blvd, Bradenton, Florida–34211

Prof. Kamal Pathak
Rajiv Academy of Pharmacy, Mathura, INDIA

Prof. V. R. Sinha
Panjab University, Chandigarh, INDIA

Prof. Pramod Tiwari
National Institute of Pharmaceutical Education and Research (NIPER), Mohali, INDIA

Prof. Anan Nanda
Faculty of Pharm. Sciences, Maharishi Dayanand University, Rohtak, INDIA

Prof. C. P. Ketare
Panjab University, Chandigarh, INDIA

Dr. Amit Bhutia
Lovely Professional University, Punjab, INDIA

Dr. Anil Ahuja
Rajiv Academy Academy of Pharmacy, Mathura, INDIA
Design of Nanostructured Lipid Carriers Ubiquinone-10 for Transdermal Treatment

M Fatchur Rochman1,2, Isnaeni1, Esti Hendradi1

1 Department of Pharmaceutics, Faculty of Pharmacy, Airlangga University, Indonesia
2 Department of Pharmaceutics, Faculty of Pharmacy, Wahid Hasyim University, Indonesia

Received: 9th Apr, 18; Revised: 25th May, 18, Accepted: 17th Jul, 18; Available Online: 25th Sep, 2018

ABSTRACT
Ubiquinone-10 is a cellular endogenous antioxidant that resides in the epidermal layer. Ubiquinone-10 can increase the production of basal membrane components, fibroblast proliferation and protect cells from oxidative damage, so with increasing age, the amount of Ubiquinone-10 body will decrease. Bioavailability and permeability of Ubiquinone-10 are very low, thus affecting the potential efficacy and absorption in Ubiquinone-10. The preparation of Ubiquinone-10 formulation needs to be done to obtain products that have good bioavailability. Nanostructured Lipid Carrier (NLCs) is a modification of the SLN system, consisting of a certain amount of lipid matrix and liquid lipids. Mixtures of solid lipids and liquid lipids can provide space for drug trapping. The system will remain in solid form by controlling the concentration of the liquid lipids to be added into the formula so that the drug release process can be controlled.

Keywords: Nanostructured Lipid Carriers, Ubiquinone-10, Transdermal Treatment.

INTRODUCTION
Ubiquinone-10 is an antioxidant that protects the body from damage caused by harmful molecules known as free radicals. Ubiquinone-10 can neutralize free radicals and help prevent damage caused by free radicals, such as cell membrane damage, DNA damage, and cell death. The antioxidant properties of Ubiquinone-10 come from the carrier function of energy. As an energy carrier, the molecules of Ubiquinone-10 will continuously pass through the redox cycle. When receiving electrons, it will be reduced and when giving electrons, it becomes oxidized. In reduced form, the Ubiquinone-10 molecule holds a somewhat loose electron, so that this Ubiquinone-10 molecule will be quite easy to take one or both of the electrons, therefore acting as an antioxidant. Ubiquinone-10 inhibits lipid peroxidation by preventing the production of peroxy lipid radicals7,10.

Ubiquinone-10 is a derivative of a lipid-soluble quinone with an isoprenoid side chain. The homolog of Ubiquinone contains 1-12 isoprene units. The dominant form of ubiquinone in humans is ubiquinone-10 (contains 10 isoprene units). In liver cells, 40-50% of the total cellular ubiquinone is located in the mitochondria, 25-30% in the core, 15-20% in the endoplasmatic reticulum, and only 5-10% in the cytosol. In vitro tests, ubiquinol (reduced form of ubiquinone) has antioxidant activity 2-3 times more potent. Ubiquinol/ubiquinone acts as a redox carrier in the respiratory chain, participating in the transfer of protons across the inner mitochondrial membrane. Ubiquinol can react with ROS and prevent direct damage to biomolecules and initiation of lipid peroxidation. Ubiquinone cannot prevent autocatalytic free radical reactions by donating a phenolic hydrogen atom, ubiquinone binding singlet oxygen and inhibiting lipid peroxidation in the membrane model3.

Nanostructured Lipid Carrier (NLC)
NLC is the development of SLN (Solid Lipid Nanoparticle) aimed at overcoming the shortcomings of SLN. SLN is identical to an oil-in-water emulsion, but the oil phase used is a solid lipid. The use of solid lipid causes the drug loading on this system is not good, as well as the occurrence of leaks or discharge of medicines from the system. In storage, the solid lipid will form a crystal structure so that the space occupied by the drug material becomes reduced. This is what causes the release of drugs from the SLN system. NLC formed from a mixture of solid and liquid lipids capable of reducing the formation of crystals in lipid and can increase drug absorption, NLC has a particle size distribution up to 500μm. NLC is the latest generation of SLN. NLC consists of a certain amount of lipid matrix and liquid lipids. The NLC remains in solid form by controlling the liquid lipid content added to the formulation, so that the controlled release of the drug to NLC can be achieved17.

Another component added to the NLC system is the surfactant. The addition of surfactants in the NLC serves to stabilize the nanoparticles formed on the system and prevent the incorporation of particles during storage16. The components used in NLC formulations are included in GRAS (Generally Regarded as Safe)15. Solid lipids that can be used on NLC systems include; stearic acid, glyceryl stearate, cetyl palmitate, and tristearin15,18,19. While liquid lipids that can be used include oleic acid, ethyl oleate, and miglyol (medium-chain triglycerides)15,19. With the
increase of liquid lipid, it will decrease the measurement an particle. Due to the increase of solid lipids, the tendency of particles to aggregate also increases. An increase in the number of liquid lipids can result in better drug trapping. This may have an effect on the formation of crystals, so the regularity of the crystal lattice is disrupted and increases the space for drug molecules which ultimately increases the efficiency of trapping. The amount of addition of the surfactant used also affects the particle size and stability of the formula. Increased surfactant concentration can decrease particle size. The number and type of surfactant optimum are able to envelop the surface of the particles. Type Of NLC

NLC Type I

NLC type I can be called imperfect imperfect model (Imperfect type), because the structural difference between the solid and liquid lipids leads to imperfections of the formation of crystals to form a larger space for drug molecules to occupy. This model was obtained at the time of solid lipid mixing with small amounts of lipid liquid.

NLC Type II

NLC type II was defined as an amorphous model as it was created when mixing certain lipids that could not crystallize after mixing. The lipid used is a solid lipid with an amorphous form. In the absence of crystallization, the tendency of the drug to get out of the system can be reduced.

NLC Type III

NLC type III referred to as multiple models. This model has been developed to increase drug charge capacity. Multiple types is a type of NLC capable of loading drugs in solid lipids, while the increased solubility of drug substances is done by adding the number of liquid lipids. In general, the drug will be more soluble in liquid lipids than in solid lipids. So in the process of making the amount of liquid lipid will be higher. During the production process, there will be a cooling process at room temperature which causes the lipid matrix particles to change from liquid to solid. The difference in mixing between the two lipids leads to a separation that will form the oil nano-compartments inside the solid lipid particles.

Advantages of NLC

NLC has the advantage of being used for controlled drug release and targeted drugs, improving pharmaceutical stability, increasing drug loading. Some of the advantages of NLC are:

Occlusive effects

Occlusive effects are influenced by particle size, lipid concentration, and the type of lipid used. Very small particles of lipid particles form high crystals and melting points of lipids are low resulting in increased occlusivity properties. The surface area of the particles in NLCs in contact with the stratum corneum can be increased and the lipids used can make the NLC become adhesive to the skin thereby increasing the penetration of the active ingredient through the stratum corneum and providing an occlusive effect on the skin.

Controlled drug release

The use of solid lipids in the NLC system causes the mobility of the drug substances in the liquids to be lower resulting in the release of drug substances gradually.

Improve drug stability

Increase in chemical stability due to the small contact of the drug with oxygen, light, moisture, ambient temperature and contamination due to drug ingredients trapped in the NLC system. NLC is able to prevent the expulsion of medicinal materials from the system because it inhibits the formation of the lipid crystals so that the stability during storage can be increased.

Have low toxicity

The composite material of the NLC system consists of solid lipids and liquid lipids that have non-irritating properties, biodegradable and safe. Generally Recognized As Safe (GRAS) so that preparations with NLC systems have low toxicity.

Increase drug trapping

High carrier capacity so that many drug molecules can be incorporated into matrix particles.

Having a low viscosity

NLC system has a low viscosity so that the molecular mobility of the active ingredient is increased so that there is no inhibitory barrier.

Transport System Of Drug

The drug transport is a mass transport process with one random movement occurs by the influence of concentration differences. Movement of molecules through a barrier with a particular mechanism is a diffusion process. The process of transport occurs through a variety of mechanisms, including molecular permeation through various mechanisms, including molecular permeation through a non porous barrier where the molecule of the compound must be dissolved beforehand into the barrier before it can penetrate, whereas in the transport through the pore, the transport speed is determined by the measured molecular size and pore diameter. The drug transport mechanism of the dosage forms occurs in two stages. The first stage, drug release from the carrier, stage second a penetrate through the barrier. The main transport process occurs in passive diffusion, ie the transport process that occurs due to the difference in concentration gradient.

Penetration Work

On percutaneous penetration occurs the transfer of active ingredients through the skin from the external environment to the blood circulation. Percutaneous absorption can be defined as a combination of molecular penetration through the skin, followed by resorption of the blood or lymphatic system of the papillary dermis and underlying layer. The penetration stage is a passive diffusion through each structure of the stratum corneum, dermis, aneksa. The skin has several layers, among others, stratum corneum is a percutaneous absorption rate inhibitor. Large and hydrophilic molecular transport will be difficult to penetrate the lipid layer of the stratum corneum because it contains 40% lipid, 40% protein, and only 20% water. The transport of lipophilic drug molecules is facilitated by dissolution to the intercellular liquid present in the stratum corneum. The absorption of a hydrophilic drug may occur through the pore or opening of the follicle and sebaceous.
The speed of drug penetration through the skin can change when the body has increased temperature. The temperature will increase in the occlusive state. In the occlusive state, water on the skin cannot evaporate and cause dehydration so that the flow of blood in the dermal layer will increase. 

**Physical properties of the active ingredients.**

**Partition coefficient**

The partition coefficient is the ratio between the drug concentration in the stratum corneum and the drug levels in the carrier. If the partition coefficient is large, then the drug will be more soluble in the carrier. If the partition coefficient is small, the drug will be more soluble in the stratum corneum than in the drug carrier so that the drug content in the large stratum corneum. The partition coefficient affects the transport speed.

**The drug's cooling**

The solution of the drug in the water determines the absorbed concentration. The more drug substances in the dissolved state the greater the drug's ability to penetrate the membrane.

**The diffusion coefficient**

The diffusion coefficients show the ability of the drug to penetrate into the stratum corneum. Usually, the drug diffusion coefficients in the stratum corneum are very low due to the very slow movement of drug molecules. If the skin condition in sickness or drug diffusion in the carrier is very slow, the percutaneous penetration rate is determined by drug release from the carrier. Part shape and size. The small particle size and spherical shape will cause the inter-particle structure to become tightly, causing an increase in the occlusivity of retained water in the stratum corneum which causes hydration and swelling so that the drug substances easily enter.

**The carrier effect**

Carrier may also affect the penetration of the drug into the skin as most of the material in one formulation is a carrier. The interaction between drug and carrier material can affect penetration because the strong affinity between the drug and the carrier causes the drug substance to be removed from the base so that the amount of medicinal ingredient in the stratum corneum decreases. There are several factors that come from the carriers that come out have an effect on the penetration:

**The nature of lipophilicity**

Carrier can affect the physical condition and permeability of the skin against the drug. The carrier composition is expected to improve the speed and amount of the drug diffusion. The lipophilic carrier will block the water so that water cannot get out and retained in the stratum corneum causing skin hydration. Hydration of the stratum corneum can increase penetration of the drug into the. The drug mixed with the carrier must be able to blend with the skin surface in sufficient concentration so that penetration can be maximized.

**Viscosity**

Absorption of the drug will increase if the carrier can easily spread to the skin surface so that penetration will increase. This can happen because when used the drug can spread to a wider surface resulting in increased absorption of the skin.
Enhancer

Increased penetration of topical medication can be achieved by the addition of several compounds capable of increasing the absorption in the skin. One of the enhancer mechanisms is by making the interaction of enhancers with polar head groups from lipids. Interaction of lipid-lipid head groups and sequences of lipids will be disrupted thus facilitating the diffusion of hydrophilic drugs. The increased flow of free water molecules between bilayers, leading to enlargement of the cross section for polar drug diffusion. Simple hydration can be used in structural modifications that result in drug penetration changes. Water is one of the most effective and safest penetration enhancers. By hydration of the stratum corneum, penetration of most drugs can be increased. Usually in the stratum corneum moisture content of 5-10%. Water content may increase by up to 50% in occlusion conditions (eg by using impermeable foil or by occlusive vehicle applications). The lipid head group disorder by polar enhancer substances may also affect the hydrophobic parts of the lipids and cause rearrangements in the bilayer region. It also explains the increased penetration of lipophilic drugs by using a lipid head group affects the penetration of hydrophilic enhancer substances. Another possibility is the lipophilic penetration enhancement interaction with the hydrocarbon chains of the lipid bilayer. Penetration of lipophilic drugs is facilitated in this way with a skeletal disorder resulting from increased fluidization by hydrocarbon chains. This change also affects the order of the polar head groups, which explains the increased penetration of hydrophilic drugs by using lipophilic enhancer substances

CONCLUSIONS

NLCs are expected to be an alternative treatment aimed at treatment for a long time and have targeted targets, then the drug can be used for the treatment of transdermal that takes a long time. It is hoped that the NLC can become a new, periodically transdermal treatment of transdermal treatment. So the treatment will be more efficient with good effectiveness, but the side effects will be less.

REFERENCE

Characterization of Nanostructured Lipid Carrier (NLC) Loaded Gel for Psoriasis. Der Pharmacia Lettre. 5 (4).